Sarepta Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sarepta Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $52 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier. More money tied up than 94% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 90% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-2.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 59% of Healthcare companies in United States.
Cash Locked Ratio
$52For every $100 of sales, $52 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier.
More money tied up than 94% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$1Sales grew 136% in 3 years, but profit fell: $1 less profit per $100 of extra sales.
Lower than 68% of Healthcare companies in United States.
Asset Productivity Ratio
+136% / +7%In 3 years sales changed by +136% while total assets changed by +7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-18.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 53% of Healthcare companies in United States.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 74% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 90% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 87% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Sarepta Therapeutics, Inc. made a loss over the last year. Sarepta Therapeutics, Inc. owes $0.52 for every $1 it owns. Sarepta Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSarepta Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.26The share price is 1.26 times Sarepta Therapeutics, Inc.'s book value per share, lower than 73% of Healthcare companies in United States.
Market cap
$1.9 BThe total market value of all of Sarepta Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 74% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.5 BWhat Sarepta Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$14.46Net worth divided by the number of shares. The share price of $18.18 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-9.5%Sarepta Therapeutics, Inc. lost 9.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
Owes vs Owns
0.52×Sarepta Therapeutics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Dividend yield
NoneSarepta Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+16%Revenue rose 16% in the year to Dec 2025, and grew 33% a year on average over 3 years.
Profit growth
LossSarepta Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-32.5%Sarepta Therapeutics, Inc. lost $32 for every $100 of revenue.
Interest cover
Not coveredSarepta Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtSarepta Therapeutics, Inc. had $100 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sarepta Therapeutics, Inc.: $1.9 B ÷ $1.5 B (30 Jun 2026) = 1.3.
What is Sarepta Therapeutics, Inc.'s return on equity?
Sarepta Therapeutics, Inc. lost 9.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
How much does Sarepta Therapeutics, Inc. owe compared with what it owns?
Sarepta Therapeutics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Does Sarepta Therapeutics, Inc. pay a dividend?
No. Sarepta Therapeutics, Inc. does not currently pay a dividend.
Is Sarepta Therapeutics, Inc.'s revenue growing?
Revenue rose 16% in the year to Dec 2025, and grew 33% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.